Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania

Reinstein, Michael J.; Sonnenberg, John; Hedberg, Thomas G.; Jones, Lynne E.; Reyngold, Polina

doi:10.2165/00044011-200323100-00006

Cited by 11 publications

(20 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unlike CBZ, OXC is not metabolized by oxidation, thus circumventing the generation of the 10,11-epoxide species thought to be responsible for much of the toxicity of CBZ. There is no established therapeutic window for OXC in contrast to CBZ; therefore, monitoring plasma concentration may only be useful in cases of intoxication [1,2,[4][5][6].…”

Section: Pharmacology Of Oxcarbazepinementioning

confidence: 99%

“…10 Bipolar depression and schizoaffective 6-16 months Randomized study of OXC (n = 4) vs lithium (n = 6) Adjunct (n = 3) and monotherapy 2/4 (50%) with no relapses on OXC vs 3/6 (50%) with no relapses on lithium [23] Wildgrube Unknown Lithium response (67%) greater than OXC response (33%) [42] Teitelnaum [2] Ghaemi et al [20] Schaffer et al [15] Comes et al…”

Section: Monotherapymentioning

confidence: 99%

“…12 1 bipolar II, 5 NOS 28.0 ± 7.6 weeks Retrospective naturalistic study Adjunct OXC showed mild/marked improvement [24] Adjunct to risperidone Improved scores on CGI, PANSS, YMRS and HAM-D scales [21] MalekAhmadi et al 24 weeks [2,7,[15][16][17]. One open-label trial, ABA design, studying the efficacy of OXC as monotherapy for acute manic, was performed in 12 bipolar I patients.…”

Section: Weeksmentioning

confidence: 99%

“…The potential serious complications of CBZ, aplastic anemia or agranulocytosis have not been observed with OXC [1]. The very low level of hepatic cytochrome P450 enzyme induction by OXC is of great advantage [1,2]. This is why OXC is generally free of significant pharmacokinetic interactions [36], although it does reduce plasma concentrations of estrogen and progesterone components of oral contraceptives (50%) [3,37] and calcium channel blockers (30%).…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

“…According to the literature, OXC is regarded as effective in acute mania and appears to reduce the dosage of neuroleptics required for the treatment of bipolar and schizoaffective disorders. Moreover, the American Psychiatric Association already advises the use of OXC as a reasonable option in the treatment of bipolar and schizoaffective patients who do not respond to established treatments (APA, 2002) [1][2][3].…”

mentioning

confidence: 99%

See 4 more Smart Citations

Oxcarbazepine in the treatment of bipolar and schizoaffective disorders

Popova¹,

Leighton²,

Bernabarre³

et al. 2007

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Oxcarbazepine is an antiepileptic drug that has been approved by the US FDA and is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children aged over 4 years. The aim of this report is to investigate the results of clinical trials in order to ascertain the efficacy and safety of oxcarbazepine for use in bipolar disorder and schizoaffective disorder. Oxcarbazepine is a keto-congener of carbamazepine with fewer side effects and drug interactions. Orally administrated oxcarbazepine is rapidly and completely absorbed and has a half-life of 9 h. Currently, there is a lack of controlled clinical trials studying the use of oxcarbazepine. In light of controlled and open-label prospective studies, it may be useful for manic symptoms in the treatment of bipolar and schizoaffective patients. Case reports, retrospective and prospective studies suggest that oxcarbazepine might have prophylactic efficacy and long-term benefit for these patients. In addition, owing to its lower propensity for drug interactions and side effects, it may be useful in the treatment of refractory patients with bipolar and schizoaffective disorder. However, most of the trials have relevant methodological shortcomings. The side-effect profile of oxcarbazepine is similar to carbamazepine, but the severity of these effects appears to be slightly less. The symptoms that are most frequently associated with the use of oxcarbazepine are asthenia, headache, dizziness, somnolence, nausea, diplopia and skin rash. Isolated cases of hyponatremic coma have been reported, thus electrolyte abnormalities should be closely monitored. Oxcarbazepine is now a generic drug, but the metabolite licarbazepine and other related compounds, such as eslicarbazepine, are currently being studied under controlled conditions and might become useful therapies for bipolar and schizoaffective disorder in the future.

show abstract

Section: Pharmacology Of Oxcarbazepinementioning

confidence: 99%